Compare BKV & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKV | CDNA |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 2022 | 2007 |
| Metric | BKV | CDNA |
|---|---|---|
| Price | $22.95 | $54.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $34.22 | $28.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.0M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 199.00 | N/A |
| EPS | 1.11 | ★ 2.13 |
| Revenue | ★ $893,781,000.00 | $48,324,000.00 |
| Revenue This Year | $69.39 | $16.01 |
| Revenue Next Year | $9.45 | $11.31 |
| P/E Ratio | ★ $20.66 | $25.21 |
| Revenue Growth | ★ 47.85 | 18.93 |
| 52 Week Low | $20.08 | $13.95 |
| 52 Week High | $32.81 | $55.16 |
| Indicator | BKV | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.86 | 68.92 |
| Support Level | N/A | $45.74 |
| Resistance Level | $27.55 | N/A |
| Average True Range (ATR) | 1.04 | 2.02 |
| MACD | -0.24 | -0.03 |
| Stochastic Oscillator | 13.62 | 81.33 |
BKV Corp is a growth-driven energy company focused on the development of natural gas-producing assets, the ownership and operation of natural gas-fired power generation assets, and selective accretive acquisitions. The company's core businesses are the production of natural gas and the generation of natural gas-fired power from its owned and operated assets, supported by a closed-loop plan, enabled by its upstream, midstream, power, and CCUS businesses.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.